通过冷沉淀法制备的血浆组分中的因子 VIII 和抗体水平。
Factor 8 and antibody levels in plasma fractions prepated by cryoprecipitation.
作者信息
Pollock A
出版信息
J Clin Pathol. 1968 Sep;21(5):635-7. doi: 10.1136/jcp.21.5.635.
Abstract
Most of the antibody activity of plasma was found to remain in the supernatant fraction following the preparation of factor-VIII-rich cryoprecipitates. The low level of antibody remaining in these cryoprecipitates indicated that they could safely be used as a source of factor VIII for replacement therapy. Washing the cryoprecipitates farther reduced their antibody titres without materially affecting their factor VIII content.
摘要
在制备富含因子VIII的冷沉淀后，发现血浆中的大部分抗体活性仍保留在上清液部分。这些冷沉淀中残留的抗体水平较低，表明它们可安全地用作替代疗法的因子VIII来源。进一步洗涤冷沉淀可降低其抗体滴度，而对其因子VIII含量没有实质性影响。
相似文献
1
Factor 8 and antibody levels in plasma fractions prepated by cryoprecipitation.
J Clin Pathol. 1968 Sep;21(5):635-7. doi: 10.1136/jcp.21.5.635.
2
Fractions rich in factor VIII.
Bibl Haematol. 1968;29:1122-6. doi: 10.1159/000384749.
3
[Cryoprecipitates rich in factor VIII. In vitro and in vivo studies].
Rev Fr Transfus. 1969 Dec;12(4):439-50. doi: 10.1016/s0035-2977(69)80110-0.
4
Clearance of cryoprecipitated factor VIII in canine hemophilia A.
Am J Vet Res. 1975 Apr;36(4 Pt.1):367-70.
5
Cryoprecipitates and blood-groups.
Lancet. 1979 Jul 28;2(8135):203. doi: 10.1016/s0140-6736(79)91473-9.
6
The preparation of a human plasma fraction by cryoprecipitation and its use in haemophilia.
Acta Clin Belg. 1968;23(3):139-52. doi: 10.1080/17843286.1968.11716675.
7
[Cryoprecipitation and dextran precipitation in obtaining factor VIII concentrates: results of redetecting antihemophilic globulin A in a patient].
Z Gesamte Inn Med. 1974 Mar 15;29(6):236-40.
8
[in vivo reappearance of injected cryoprecopitate (factor VIII concentrates) in patients with hemophilia A].
Z Gesamte Inn Med. 1973 Oct 15;28(20):608-14.
9
Pre-assayed AHF concentrate therapy for hemophilia.
Bibl Haematol. 1968;29:1160-5. doi: 10.1159/000384756.
10
Treatment of haemophilia (factor-8 deficiency) with human antihaemophilic factor prepared by the cryoprecipitate process.
Lancet. 1967 Mar 4;1(7488):457-60. doi: 10.1016/s0140-6736(67)91087-2.
本文引用的文献
1
PREVENTION OF RH-HAEMOLYTIC DISEASE: A THIRD REPORT.
Br Med J. 1965 Jan 30;1(5430):279-83. doi: 10.1136/bmj.1.5430.279.
2
Antepartum management of Rh hemolytic disease.
Bull Sloane Hosp Women Columbia Presbyt Med. 1962;8:147-58.
3
A one-stage factor VIII (antihaemophilic globulin) assay and its use on venous and capillary plasma.
Thromb Diath Haemorrh. 1962 May 15;7:215-28.
4
Experimental studies on the prevention of Rh haemolytic disease.
Br Med J. 1961 May 27;1(5238):1486-90. doi: 10.1136/bmj.1.5238.1486.
5
The factor-8 activity in fresh and stored plasma.
Br J Haematol. 1967 Jan;13(1):42-59. doi: 10.1111/j.1365-2141.1967.tb08693.x.
6
Production of high-potency concentrates of antihemophilic globulin in a closed-bag system.
N Engl J Med. 1965 Dec 30;273(27):1443-7. doi: 10.1056/NEJM196512302732701.
7
Treatment of haemophilia (factor-8 deficiency) with human antihaemophilic factor prepared by the cryoprecipitate process.
Lancet. 1967 Mar 4;1(7488):457-60. doi: 10.1016/s0140-6736(67)91087-2.
8
The effect of cryoprecipitate concentrate in patients with classical haemophilia.
Lancet. 1967 Jan 28;1(7483):191-2. doi: 10.1016/s0140-6736(67)91828-4.
9
Dose of anti-D gamma-globulin in prevention of Rh-haemolytic disease of the newborn.
Br Med J. 1966 Jan 22;1(5481):213-4. doi: 10.1136/bmj.1.5481.213.
Zotero 插件